| Cas No.: | 1542705-92-9 |
| Chemical Name: | CB-5083 |
| Synonyms: | CB-5083;CB5083;591IV6UL6J;AK173785;1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide;1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide;BCP23807;CB 5083;S8101;J3.551.815K;1-(7,8-Dihydro-4-((phenylmethyl)amino)-5H-pyrano(;1542705-92-9;CCG-268805;BDBM50500325;p97 Inhibitor CB-5083;HY-12861;UNII-591IV6UL6J;BRD-K49048664-001-02-0;CB-5083; CB 5083;EX-A773;MFCD28963914;BRD-K49048664-001-01-2;(1-(4-(benzylamino)-5H,7H,8H-pyrano(4,3-d)pyrimidin-2-yl))-2-methyl-1H-indole-4-carboxamide;DTXSID801022542;BC177445;1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide;CHEMBL3747513;CB 5083 [WHO-DD];CB-5083?;AC-29018;NSC786100;CS-5405;NSC-786100;JDP;AS-55872;AKOS025396184;NCGC00481317-01;SCHEMBL15421452;1-[4-(BENZYLAMINO)-5H,7H,8H-PYRANO[4,3-D]PYRIMIDIN-2-YL]-2-METHYLINDOLE-4-CARBOXAMIDE;1-(7,8-Dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide;1H-Indole-4-carboxamide, 1-(7,8-dihydro-4-((phenylmethyl)amino)-5H-pyrano(4,3-d)pyrimidin-2-yl)-2-methyl-;NCGC00481317-03;DA-71987;HMS3873E13 |
| SMILES: | O1C([H])([H])C([H])([H])C2=C(C(N([H])C([H])([H])C3C([H])=C([H])C([H])=C([H])C=3[H])=NC(=N2)N2C(C([H])([H])[H])=C([H])C3=C(C(N([H])[H])=O)C([H])=C([H])C([H])=C23)C1([H])[H] |
| Formula: | C24H23N5O2 |
| M.Wt: | 413.4717 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|